Role of HDACs in optic nerve damage-induced nuclear atrophy of retinal ganglion cells

Neuroscience Letters

Volumn 625, Issue , 2016, Pages 11-15

  Schmitt, Heather M ^a   Schlamp, Cassandra L ^a   Nickells, Robert W ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Apoptosis; Glaucoma; Heterochromatin; Histone deacetylase (HDAC); Neurodegeneration; Nuclear atrophy; Optic nerve injury; Retinal ganglion cell

Indexed keywords

HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE INHIBITOR;

APOPTOSIS; CANCER THERAPY; CELL DEATH; CHROMATIN ASSEMBLY AND DISASSEMBLY; DEACETYLATION; EPIGENETICS; GLAUCOMA; HETEROCHROMATIN; HUMAN; NERVE CELL DIFFERENTIATION; NERVE FIBER TRANSECTION; OPTIC NERVE ATROPHY; OPTIC NERVE DISEASE; OPTIC NERVE LESION; PRIORITY JOURNAL; RETINA GANGLION CELL; REVIEW; VISUAL IMPAIRMENT; ANIMAL; ATROPHY; DISEASE MODEL; ENZYMOLOGY; GENETIC EPIGENESIS; METABOLISM; NERVE CRUSH; OPTIC NERVE DISEASES; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; ATROPHY; DISEASE MODELS, ANIMAL; EPIGENESIS, GENETIC; GLAUCOMA; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; NERVE CRUSH; OPTIC NERVE DISEASES; RETINAL GANGLION CELLS; SIGNAL TRANSDUCTION;

EID: 84952333744     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2015.12.012     Document Type: Review

References (42)

1. McKinnon S.J., Schlamp C.L., Nickells R.W. Mouse models of retinal ganglion cell death and glaucoma. Exp. Eye Res. 2009, 88:816-824.
2. Janssen K.T., Mac Nair C.E., Dietz J.A., Schlamp C.L., Nickells R.W. Nuclear atrophy of retinal ganglion cells precedes the bax-dependent stage of apoptosis. Invest. Ophthalmol. Vis. Sci. 2013, 54:1805-1815.
3. Pelzel H.R., Schlamp C.L., Nickells R.W. Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis. BMC Neurosci. 2010, 11:62.
4. Schmitt H.M., Pelzel H.R., Schlamp C.L., Nickells R.W. Histone deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death after acute optic nerve injury. Mol. Neurodegener. 2014, 9:39.
5. Tiwari S., Dharmarajan S., Shivanna M., Otteson D.C., Belecky-Adams T.L. Histone deacetylase expression patterns in developing murine optic nerve. BMC Dev. Biol. 2014, 14:30.
6. Wang Z., Zang C., Cu K., Schones D.E., Barski A., Peng W., Zhao K. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009, 138:1019-1031.
7. Baltan S., Morrison R.S., Murphy S.P. Novel protective effects of histone deacetylase inhibition on stroke and white matter ischemic injury. Neurotherapeutics 2013, 10:798-807.
8. Duncan C.E., An M.C., Papanikolaou T., Rugani C., Vitelli C., Ellerby L.M. Histone deacetylase-3 interacts with ataxin-7 and is altered in a spinocerebellar ataxia type 7 mouse model. Mol. Neurodegener. 2013, 8:42.
9. Jia H., Pallos J., Jacques V., Lau A., Tang B., Cooper A., Syed A., Purcell J., Chen Y., Sharma S., Sangrey G.R., Darnell S.B., Plasterer H., Sadri-Vakili G., Gottesfeld J.M., Thompson L.M., Rusche J.R., Marsh J.L., Thomas E.A. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol. Dis. 2012, 46:351-361.
10. Malvaez M., McQuown S.C., Rogge G.A., Astarabadi M., Jacques V., Carreiro S., Rusche J.R., Wood M.A. HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:2647-2652.
11. Fan J., Alsarraf O., Dahrouj M., Platt K.A., Chou C.J., Rice D.S., Crosson C.E. Inhibition of HDAC2 protects the retina from ischemic injury. Invest. Ophthalmol. Vis. Sci. 2013, 54:4072-4080.
12. Dillon N., Festenstein R. Unravelling heterochromatin: competition between positive and negative factors regulates accessibility. Trends Genet. 2002, 18:252-258.
13. Kerr J.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972, 26:239-257.
14. Gavrieli Y., Sherman Y., Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 1992, 119:493-501.
15. Enari M., Sakahira H., Yokoyama H., Okawa K., Iwamatsu A., Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998, 391:43-50.
16. Pelzel H.R., Schlamp C.L., Waclawski M., Shaw M.K., Nickells R.W. Silencing of Fem1cR3 gene expression in the DBA/2 J mouse precedes retinal ganglion cell death and is associated with histone deacetylase activity. Invest. Ophthalmol. Vis. Sci. 2012, 53:1428-1435.
17. Yang Z., Quigley H.A., Pease M.E., Yang Y., Qian J., Valenta D., Zack D.J. Changes in gene expression in experimental glaucoma and optic nerve transection: the equilibrium between protective and detrimental mechanisms. Invest. Ophthalmol. Vis. Sci. 2007, 48:5539-5548.
18. Hellstrom M., Ruitenberg M.J., Pollett M.A., Ehlert E.M., Twisk J., Verhaagen J., Harvey A.R. Cellular tropism and transduction properties of seven adeno-associated viral vector serotypes in adult retina after intravitreal injection. Gene Ther. 2009, 16:521-532.
19. Lebrun-Julien F., Suter U. Combined HDAC1 and HDAC2 depletion promotes retinal ganglion cell survival after injury through reduction of p53 target gene expression. ASN Neuro 2015, 7.
20. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 2007, 5:981-989.
21. Biermann J., Grieshaber P., Goebel U., Martin G., Thanos S., Di Giovanni S., Lagreze W.A. Valproic acid-mediated neuroprotection and regeneration in injured retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2010, 51:526-534.
22. Biermann J., Boyle J., Pielen A., Lagreze W.A. Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells. Mol. Vis. 2011, 17:395-403.
23. Chindasub P., Lindsey J.D., Duong-Polk K., Leung C.K., Weinreb R.N. Inhibition of histone deacetylases 1 and 3 protects injured retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 2013, 54:96-102.
24. Alsarraf O., Fan J., Dahrouj M., Chou C.J., Yates P.W., Crosson C.E. Acetylation preserves retinal ganglion cell structure and function in a chronic model of ocular hypertension. Invest. Ophthalmol. Vis. Sci. 2014, 55:7486-7493.
25. Semaan S.J., Li Y., Nickells R.W. A single nucleotide polymorphism in the Bax gene promoter affects transcription and influences retinal ganglion cell death. ASN Neuro 2010, 2:e00032.
26. Bardai F.H., D'Mello S.R. Selective toxicity by HDAC3 in neurons: regulation by Akt and GSK3beta. J. Neurosci. 2011, 31:1746-1751.
27. Uo T., Veenstra T.D., Morrison R.S. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J. Neurosci. 2009, 29:2824-2832.
28. Brochier C., Dennis G., Rivieccio M.A., McLaughlin K., Coppola G., Ratan R.R., Langley B. Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons. J. Neurosci. 2013, 33:8621-8632.
29. Chao C., Wu Z., Mazur S.J., Borges H., Rossi M., Lin T., Wang J.Y., Anderson C.W., Appella E., Xu Y. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol. Cell. Biol. 2006, 26:6859-6869.
30. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10:431-442.
31. Horvath M.M., Wang X., Resnick M.A., Bell D.A. Divergent evolution of human p53 binding sites: cell cycle versus apoptosis. PLoS Genet. 2007, 3:e127.
32. Qian H., Wang T., Naumovski L., Lopez C.D., Brachmann R.K. Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites. Oncogene 2002, 21:7901-7911.
33. Millau J.F., Bandele O.J., Perron J., Bastien N., Bouchard E.F., Gaudrea L., Bell D.A., Drouin R. Formation of stress-specific p53 binding patterns is influenced by chromatin but not by modulation of p53 binding affinity to response elements. Nucleic Acids Res. 2011, 39:3053-3063.
34. Peng S., Zhao S., Yan F., Cheng J., Huang L., Chen H., Liu Q., Ji X., Yuan Z. HDAC2 selectively regulates FOXO3a-mediated gene transcription during oxidative stress-induced neuronal cell death. J. Neurosci. 2015, 35:1250-1259.
35. Langley B., D'Annibale M.A., Suh K., Ayoub I., Tolhurst A., Bastan B., Yang L., Ko B., Fisher M., Cho S., Beal M.F., Ratan R.R. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J. Neurosci. 2008, 28:163-176.
36. Bratland A., Dueland S., Hollywood D., Flatmark K., Ree A.H. Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy. Radiat. Oncol. 2011, 6:33.
37. Chen P.S., Wang C.C., Bortner C.D., Peng G.S., Wu X., Pang H., Lu R.B., Gean P.W., Chuang D.M., Hong J.S. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007, 149:203-212.
38. Dietz K.C., Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol. Res. 2010, 62:11-17.
39. Cudkowicz M.E., Andres P.L., Macdonald S.A., Bedlack R.S., Choudry R., Brown R.H., Zhang H., Schoenfeld D.A., Shefner J., Matson S., Matson W.R., Ferrante R.J., A.L.S.Northeast V.A.A.L.S.R.C.National Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009, 10:99-106.
40. Darras B.T., Kang P.B. Clinical trials in spinal muscular atrophy. Curr. Opin. Pediatr. 2007, 19:675-679.
41. Piepers S., Veldink J.H., de Jong S.W., van der Tweel I., van der Pol W.L., Uijtendaal E.V., Schelhaas H.J., Scheffer H., de Visser M., de Jong J.M., Wokke J.H., Groeneveld G.J., van den Berg L.H. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann. Neurol. 2009, 66:227-234.
42. Soragni E., Miao W., Iudicello M., Jacoby D., De Mercanti S., Clerico M., Longo F., Piga A., Ku S., Campau E., Du J., Penalver P., Rai M., Madara J.C., Nazor K., O'Connor M., Maximov A., Loring J.F., Pandolfo M., Durelli L., Gottesfeld J.M., Rusche J.R. Epigenetic therapy for Friedreich ataxia. Ann. Neurol. 2014, 76:489-508.